Decision to restrict thimerosal in immunizations could impact future vaccine availability on a global scale

A critical federal vaccine panel has recommended against seasonal influenza vaccines containing a specific preservative – a change likely to send shock through the global medical and scientific community and possibly impact future vaccine availability.

The panel was unilaterally remade by health secretary Robert F Kennedy Jr, a vaccine skeptic who has urged against the use of thimerosal despite a lack of evidence of real-world harm.

Across three votes, members voted in favor of restricting thimerosal in seasonal influenza vaccines across all age groups – with five in favor of the restriction, one abstention and one vote against.

“The risk from influenza is so much greater than the nonexistent – as far as we know – risk from thimerosal,” said Dr Cody Meissner, a panel member and professor of pediatrics at Dartmouth’s Geisel School of Medicine who was the lone “no” vote.